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regulators across 1,000 paediatric cancer genomes
Robert Huether1,*, Li Dong2,*, Xiang Chen1, Gang Wu1, Matthew Parker1, Lei Wei1, Jing Ma2,
Michael N. Edmonson1, Erin K. Hedlund1, Michael C. Rusch1, Sheila A. Shurtleff2, Heather L. Mulder3,
Kristy Boggs3, Bhavin Vadordaria3, Jinjun Cheng2, Donald Yergeau3, Guangchun Song2, Jared Becksfort1,
Gordon Lemmon1, Catherine Weber2, Zhongling Cai2, Jinjun Dang2, Michael Walsh4, Amanda L. Gedman2,
Zachary Faber2, John Easton3, Tanja Gruber2,4, Richard W. Kriwacki5, Janet F. Partridge6, Li Ding7,8,9,
Richard K. Wilson7,8,9, Elaine R. Mardis7,8,9, Charles G. Mullighan2, Richard J. Gilbertson10, Suzanne J. Baker10,
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Studies of paediatric cancers have shown a high frequency of mutation across epigenetic
regulators. Here we sequence 633 genes, encoding the majority of known epigenetic
regulatory proteins, in over 1,000 paediatric tumours to deﬁne the landscape of somatic
mutations in epigenetic regulators in paediatric cancer. Our results demonstrate a marked
variation in the frequency of gene mutations across 21 different paediatric cancer subtypes,
with the highest frequency of mutations detected in high-grade gliomas, T-lineage acute
lymphoblastic leukaemia and medulloblastoma, and a paucity of mutations in low-grade
glioma and retinoblastoma. The most frequently mutated genes are H3F3A, PHF6, ATRX,
KDM6A, SMARCA4, ASXL2, CREBBP, EZH2, MLL2, USP7, ASXL1, NSD2, SETD2, SMC1A and
ZMYM3. We identify novel loss-of-function mutations in the ubiquitin-speciﬁc processing
protease 7 (USP7) in paediatric leukaemia, which result in decreased deubiquitination
activity. Collectively, our results help to deﬁne the landscape of mutations in epigenetic
regulatory genes in paediatric cancer and yield a valuable new database for investigating the
role of epigenetic dysregulations in cancer.
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G
enome-wide mutation proﬁling of paediatric cancer has
yielded important insights into the molecular pathology
of the major subtypes of cancer seen in children1. Two
general observations to emerge from these studies are that
paediatric cancers on average contain fewer somatic mutations
than comparable tumours occurring in adults; and that genes that
encode proteins involved in epigenetic regulation are mutated at a
high frequency in a subset of paediatric cancers. A striking
example of the latter are mutations in histone 3 (H3F3A,
encoding H3.3 and HIST1H3B, encoding H3.1) that cause a
p.Lys27Met amino-acid substitution in up to 78% of diffuse
intrinsic pontine glioma—a highly aggressive subtype of
paediatric brain tumour2,3. Additional epigenetic regulators
recurrently mutated in paediatric cancers include CREBBP,
EED, EP300, EZH2, PHF6 and SETD2 in acute lymphoblastic
leukemia4–6; CHD7, HDAC9, KDM4C, KDM6A, MLL2,
SMARCA4 and ZMYM3 in medulloblastoma (MB)7; and ATRX
in neuroblastoma and high-grade glioma (HGG)2,8.
To extend these observations, we determine the frequency of
somatic mutations in genes directly implicated in epigenetic
regulation across each of the major subtypes of paediatric cancer
as part of the St Jude Children’s Research Hospital–Washington
University Pediatric Cancer Genome Project1. A total of
633 epigenetic regulatory genes in 1,020 paediatric cancers
representing 21 different cancer subtypes including brain
tumours, solid tumours and leukaemias are sequenced. Our
comprehensive analysis helps to deﬁne the landscape of
mutations in epigenetic regulatory genes in paediatric cancer
and provides a database that should be of signiﬁcant value in
elucidating the role of epigenetic dysregulation in cancer.
Results
Somatic mutations in epigenetic regulatory genes. The 633
epigenetic regulatory genes analysed in this study include
enzymes that covalently modify histones including histone wri-
ters (n¼ 159) and histone erasers (n¼ 55); the proteins that bind
histone writers (n¼ 65) or histone erasers (n¼ 20); histones
(n¼ 88); histone readers (n¼ 116); chromatin remodellers
(n¼ 72); and enzymes that covalently modify DNA (n¼ 58)
(Fig. 1a, Supplementary Data 1). These genes were sequenced in
1,020 paediatric cancers representing 21 different cancer subtypes
including brain tumours (4 subtypes), solid tumours (6 subtypes)
and leukaemias (11 subtypes; Table 1). DNA samples from both
tumour and matched germ line were analysed by either whole-
genome sequencing (WGS, n¼ 434), whole-exome sequencing
(WES, n¼ 244) or custom-designed capture sequencing of all
coding exons of the 633 genes (CC, n¼ 426; Table 1 and
Supplementary Data 2). The average read depth for WGS, WES
and CC is 30x, 100x and 342x, respectively. Across the entire
cohort, 96.7% of the coding exons of the 633 genes had coverage
420x. Because of the variation in sequencing methods used
across the cohort, we limited our mutation analyses to the
detection of single-nucleotide variants (SNVs) and small inser-
tions/deletions (indels). This analysis yielded a 490% power to
detect mutations that occurred with a mutant allele fraction
(MAF) of Z0.3, and thus focuses on mutations in the dominant
malignant clone (Supplementary Fig. 1; Supplementary Data 3
and 4). All identiﬁed non-silent coding region mutations were
experimentally validated by an independent sequencing platform
resulting in a total of 668 validated somatic mutations, with 62%
(414) occurring with a MAF 430%.
Of the 633 genes, 62 were recurrently mutated across the
patient cohort, with an additional 128 genes mutated in a single
case (Supplementary Fig. 2 and Supplementary Data 5). The
paediatric tumours that had the highest frequency of mutations in
epigenetic genes were HGGs, T-lineage acute lymphoblastic
leukaemia (TALL) and MB (43–59% of cases in these tumour
subtypes had a mutation in an epigenetic gene in the dominant
tumour clone, Fig. 1b). Osteosarcoma also exhibited high rates of
mutation in epigenetic regulatory genes; however, the high
background mutation rate in these tumours suggest that the
majority of the epigenetic regulatory gene mutations in this
cancer subtype were passenger rather than driver mutations
(Supplementary Data 5). Importantly, several paediatric cancers
were notable for almost a complete absence of mutations in
epigenetic regulators including low-grade gliomas (LGG), retino-
blastoma and infant leukaemia (Fig. 1b). However, it is important
to remember that the majority of infant leukaemias contain
a translocation involving the MLL gene and thus have an
alteration in a key epigenetic regulator as part of the leukaemia’s
initiating lesions9.
Most frequently mutated epigenetic regulatory genes. The most
frequently mutated epigenetic regulatory gene in paediatric cancer
(mutated in ﬁve or more cases) were H3F3A, PHF6, ATRX,
KDM6A, SMARCA4, ASXL2, CREBBP, EZH2, MLL2, USP7,
SETD2, ASXL1, NSD2, SMC1A and ZMYM3 (Fig. 1c;
Supplementary Table 1 and Supplementary Data 5). Although
each of these genes has been implicated in cancer, USP7, SMC1A
and ASXL2 have only been reported to be mutated in a single
paediatric case each, and are rarely mutated in adult cancers
(http://cancer.sanger.ac.uk/cosmic). Importantly, a majority of the
top 15 mutated genes were found to be mutated in multiple dif-
ferent paediatric cancer subtypes. The only exceptions were
mutations in ASXL2, NSD2, PHF6, SETD2 and USP7, which were
identiﬁed in leukaemias but not in brain or solid tumours.
Mutations in at least one of the top 15 genes were found in 23% of
the paediatric brain tumours, 15% of paediatric leukaemias, but
only in 7% of paediatric solid tumours. When we extend this
analysis to all recurrently mutated epigenetic regulators (mutated
in two or more cases), brain tumours (30%) and leukaemias (30%)
share the highest frequency of cases containing mutations in
epigenetic regulators, followed by paediatric solid tumours (17%).
Consistent with previous reports, the identiﬁed mutations in
PHF6, KDM6A, ATRX, MLL2, CREBBP, SETD2, SMARCA4,
ASXL2, ASXL1 and ZMYM3 are predicted to result in a loss-of-
function (Supplementary Table 1). By contrast, the NSD2
p.E1099K mutation has recently been shown to lead to enhanced
histone methyltransferase activity10, whereas the p.K27M
mutation in H3F3A eliminates the ability of this residue to
undergo normal regulatory post-translational modiﬁcations and
confers a gain-of-function activity that leads to a block in the
trimethylation of all H3 in the cell including the wild-type
protein11,12. Although both activating and inactivating mutations
of EZH2 have been previously reported6,13, we primarily detected
EZH2-inactivating mutations in paediatric cancer. Finally,
although the functional signiﬁcance of the identiﬁed cohesion
subunit SMC1A missense mutations remains to be determined,
some of the identiﬁed somatic mutations have been observed as
germ line mutations in patients with Cornelia de Lange
syndrome14.
The most frequently mutated epigenetic proteins in paediatric
cancer function within a network of eight epigenetic regulatory
complexes that include the Set1 (compass/compass-like)15,
mixed lineage leukaemia (MLL)16, activating signal
cointegrator-2 containing (ASCOM)17, nucleosome remodelling
and deacetylation (NuRD)18, polycomb repressor 2 (PRC2)19, the
SWI/SNF containing (BAF/PBAF)20, CREBBP/EP300 (CREB)
complex21 and the DNMT1/USP7/UHRF1 (DUU)22 (Fig. 2;
Supplementary Data 5 and 6). Nearly half of all proteins
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4630
2 NATURE COMMUNICATIONS | 5:3630 | DOI: 10.1038/ncomms4630 |www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
contained within these complexes are mutated at least once in
paediatric cancer. No signiﬁcant differences were detected in the
frequency of mutations within the BAF/PBAF and inter-related
MLL/ASCOM/compass complexes across the paediatric cancer
subtypes analysed. By contrast, over half of the mutations within
the CREB, PRC2 and NuRD complexes occurred in paediatric
leukaemias, and all of the mutations in the DUU complex, which
regulates DNA methylation and histone deubiquitination, were
identiﬁed in leukaemias. Of particular note, novel mutations were
observed in the ubiquitin-speciﬁc processing protease 7 (USP7).
Loss-of-function mutations in USP7. The deubiqutinase USP7





































































































































































































Histone writer 0.00 0.10 0.05 0.00 0.21 0.08 0.10 0.16 0.05 0.00 0.12 0.12 0.16 0.16 0.10 0.15 0.12 0.18 0.06 0.05 0.04
Histone eraser 0.01 0.10 0.03 0.00 0.00 0.03 0.06 0.03 0.00 0.02 0.18 0.06 0.08 0.04 0.02 0.05 0.00 0.00 0.00 0.00 0.00
Histone reader 0.09 0.09 0.05 0.01 0.16 0.11 0.13 0.11 0.05 0.00 0.27 0.08 0.00 0.04 0.05 0.00 0.08 0.09 0.03 0.00 0.00
Remodel chromatin 0.02 0.06 0.00 0.00 0.00 0.11 0.05 0.03 0.00 0.00 0.02 0.02 0.03 0.06 0.05 0.00 0.00 0.00 0.03 0.00 0.02
DNA modifier 0.00 0.01 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.04 0.02 0.08 0.00 0.02 0.05 0.00 0.00 0.06 0.03 0.02
0.46 0.00 0.03 0.01 0.05 0.00 0.00 0.00 0.00 0.00 0.03 0.01 0.03 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Bind histone eraser 0.02 0.13 0.03 0.00 0.00 0.03 0.02 0.00 0.05 0.00 0.03 0.08 0.03 0.08 0.02 0.05 0.00 0.00 0.00 0.00 0.00
Bind histone writer 0.00 0.06 0.00 0.00 0.11 0.03 0.03 0.00 0.05 0.00 0.08 0.02 0.03 0.04 0.07 0.05 0.00 0.00 0.00 0.03 0.02
0.58 0.43 0.13 0.02 0.53 0.35 0.31 0.24 0.21 0.02 0.56 0.39 0.38 0.34 0.32 0.25 0.20 0.18 0.18 0.10 0.07
Histone
Total
Figure 1 | The landscape of somatic mutations in epigenetic regulators in 21 paediatric cancer subtypes. (a) Eight classes of epigenetic genes were
interrogated across the cohort (histone writer, bind histone writer, histone eraser, bind histone eraser, histone, histone reader, chromatin modiﬁer
and DNA modiﬁer), with the numbers of genes within each class indicated. (b) Fraction of tumours in each cancer subtype with at least one mutation in
each class of epigenetic genes. Only sequence mutations (that is, SNVs and indels) with a MAF 40.3 (that is, present in the dominant clone) were
included in the analysis. Abbreviations are deﬁned in Table 1. (c) Top 15 most frequently mutated genes are colour coded by class.
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proteins including the tumour suppressor p53 (ref. 23), PTEN24,
the DNA methyltransferase DNMT1 (ref. 22) and histone H2B25.
Nine USP7 mutations were detected in eight patients in our study
(Fig. 3a). There were ﬁve frameshift mutations (T177fs, V203fs,
R340fs, D380fs and D483fs) that would encode truncated
proteins that lack the full catalytic domain and four missense
















High-grade glioma (HGG) 36 45 3 0 3 0 81
Low-grade glioma (LGG) 35 0 48 0 0 0 83
Medulloblastoma (MB) 36 0 49 0 15 0 70
Ependymoma (EPD) 40 0 0 0 0 0 40
Solid tumour
Neuroblastoma (NBL) 38 0 79 0 17 0 100
Retinoblastoma (RB) 4 0 46 0 3 0 47
Adrenocortical carcinoma (ACT) 20 18 0 0 0 0 38
Rhabdomyosarcoma (RHB) 13 3 26 0 3 2 37
Osteosarcoma (OS) 19 0 2 0 2 0 19
Ewing’s sarcoma (EWS) 19 0 0 0 0 0 19
Leukaemia
Infant (INF) acute lymphoblastic leukaemia (ALL) 23 6 33 0 7 0 55
Mixed lineage leukaemia (MLL) 0 20 0 0 0 0 20
T-lineage ALL (TALL) 12 3 89 0 10 3 91
ETV/RUNX1 translocation ALL (ETV) 50 1 0 1 0 0 50
Philadelphia chromosome-positive ALL (PHALL) 24 18 0 2 0 0 40
TLS-ERG translocation ALL (ERG) 14 12 0 1 0 0 25
Hypodiploid ALL (HYPO) 20 17 4 0 4 0 37
E2A/PBX1 translocation ALL (E2A) 10 24 0 1 0 0 33
Core binding factor acute myeloid leukaemia (CBF) 17 66 4 0 4 0 83
Acute megakaryoblastic leukaemia (AMLM7) 4 11 2 4 2 2 11
Other AML (AML) 0 0 41 0 0 0 41
Total pairs 434 244 426 9 70 7 1020
Each sample represents a tumour/germ line pair and is categorized by the type of cancer (brain, solid and leukaemia). The numbers of samples sequenced by each method (whole-genome sequencing





















































Figure 2 | Epigenetic complexes affected by recurrently mutated proteins in paediatric cancer. A subset (35%) of the recurrently mutated
epigenetic regulatory proteins (green circles) function within one or more of the eight key epigenetic protein complexes (red nodes). Individual somatic
mutation were also detected in additional components of these complexes (blue circles), whereas other components were never found to be mutated
within our patient cohort (white circles). The size of each green circle is proportional to the number of mutated samples. The distance between the
circles and the central complex node indicates whether the protein is a core (short) or transient (long) component of the complex. Recurrently mutated
proteins that do not belong to one of these core complexes are presented on the right as unattached circles. The colour of each protein name
conforms to the colour scheme for epigenetic regulatory classes presented in Fig. 1.
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mutations (C300R, D305G, A381T, Q821R). Three of the
missense mutations occurred within the catalytic domain and
based on the crystal structure of USP7, reside at the binding
interface between the catalytic domain of USP7 and ubiquitin
(Fig. 3b), a region that when mutated has been shown to impair
ubiquitin binding26. C300R is predicted to structurally perturb
one side of the USP7 ubiquitin binding pocket, and A381T and
D305G alter interactions with key ubiquitin binding residues
(Supplementary Figs 3–5). All except one of the USP7 mutations
(A381T) were found in TALL resulting in an overall mutation
frequency of 8% in TALL. Of the seven TALL cases with a USP7
mutation, none had somatic mutations in TP53.
To directly assess the functional consequences of the USP7
mutations identiﬁed in paediatric ALL, we transfected wild-type
and mutant USP7 (C300R and D305G) into 293T cells and
assessed their effect on the level of mono-ubiquitinated H2B-
K120, a known target of USP7 (ref. 25). Transfection resulted in
similar levels of expression of the wild-type and mutant USP7
proteins (Fig. 3c,d and Supplementary Fig. 6). As expected,
enforced overexpression of wild-type USP7 led to marked
reduction in the amount of mono-ubiquitinated H2B-K120
(Fig. 3e,f and Supplementary Fig. 6). By contrast, expression of
the USP7 mutants failed to alter the level of mono-ubiquitinated
H2B-K120 (Fig. 3e,f and Supplementary Fig. 6).
Discussion
By performing sequence analysis on the entire genomic
complement of genes that encode epigenetic regulatory proteins
in over 1,000 paediatric cancer samples, we have generated an
initial view of the somatic mutational landscape of these genes
across 21 different paediatric cancer subtypes, including the
predominant forms of leukaemia, brain tumours and solid
malignancies seen in the paediatric population. Although our
analysis is limited to SNVs and indels, these results demonstrate a
marked variation in the frequency of mutations seen in the three
major paediatric tumour types, with 30% of paediatric brain
tumours and leukaemias containing mutations compared with
only 17% of paediatric solid tumours. Moreover, speciﬁc subtypes
of brain tumours and leukaemias exhibited an exceptionally high
frequency of mutations in epigenetic regulator genes including
46% of HGGs with mutations in histone H3 (this frequency
increasing to 78% for pontine gliomas); 43% of the MBs and 56%
of TALLs with mutations in histone writers, erasers, and readers.
At the other end of the spectrum were LGG and retinoblastoma,
two tumour types that had almost no mutations within epigenetic
regulatory genes.
Not only did the frequency of somatic mutation of these genes
vary across the tumour types, but also the speciﬁc genes mutated
showed some variation between tumour types. Focusing on the
most commonly mutated genes, which function as part of eight
key epigenetic protein complexes including PRC2, NuRD, MLL,
ASCOM, compass, BAF/PBAF, CREB and DUU, we observed
that over half of the mutations within the CREB, PRC2 and
NuRD complexes occurred in paediatric leukaemias, and all of
the mutations in the DUU complex were identiﬁed in leukaemias.
By contrast, no signiﬁcant differences were detected in the
frequency of mutations within the BAF/PBAF and inter-related
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Figure 3 | Novel ALL-speciﬁc mutations of USP7. (a) Location of the identiﬁed USP7 somatic mutations relative to the TRAF (tumour necrosis factor
receptor-associated factor), catalytic and HUBL1-5 (USP7/HAUSP ubiquitin-like domain) domains (coloured red, green, black, orange, teal, purple
and blue, respectively). Mutations C300R, D483fs and Q821R occurred at MAFo30%, whereas all other mutations occurred with MAF430% and thus
represent the dominant malignant clone. (b) Location of the missense somatic mutations (C300R, D305G and A381T: magenta space ﬁlled)
within the USP7 catalytic domain (green cartoon)–ubiquitin (peach cartoon) interface. Speciﬁc residues and interactions between USP7 and ubiquitin are
shown as sticks and black dots and further described in Supplementary Figs 3–5. (c,d) 293T cells were transfected with USP7 wild-type (WT) or mutant
constructs as indicated. Protein extracts were prepared at 72 h post transfection and subjected to western blot analysis using antibodies speciﬁc
to the indicated proteins. Bars represent mean of protein band intensities of 3 replicates±s.e.m. (e,f). The level of histone H2B ubiquityl Lys120
(H2BK120ub1) and total H2B were detected at 72 h by immunoblot using an antibody speciﬁc for mono-ubiquitinated and total H2B. Bars represent mean
of protein band intensities of three replicates±s.e.m. NT, untransfected control. The statistical signiﬁcance of the changes observed between wild
type and USP7 mutants were assessed by t-test with *Po0.05 and **Po0.01.
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Within the DUU complex, we identiﬁed the recurrent somatic
mutation of the USP7 gene, which encodes a deubiquitinase that
interacts with p53, MDM2, DNMT1/UHRF1 and histones.
Although rare, somatic mutations of USP7 have been found in
adult cancers (http://cancer.sanger.ac.uk/cosmic), our structural
modelling predicts that they would be well tolerated and thus
likely represent passenger mutations (Supplementary Fig. 7 and
Supplementary Table 2). By contrast, in paediatric cancer the
majority of USP7 mutations identiﬁed are loss-of-function
mutations including frameshift mutations within the catalytic
domain that would encode truncated USP7 proteins and missense
mutations that have reduced deubiquitinase activity. Importantly,
the paediatric USP7 mutations were exclusively detected in
leukaemias, with six of the seven leukaemias containing a
mutation classiﬁed as non-ETP (or standard) TALL (6/46
(13%) of non-ETP TALLs contain a mutation in this gene).
Deﬁning the key intracellular proteins affected by the altered
USP7 function and how these changes speciﬁcally contribute to
the establishment of the non-ETP TALL malignant clone remains
to be investigated.
Similarly, understanding how the other identiﬁed mutations
alter the epigenetic landscape of a cell and contribute to
transformation remains to be determined. This will require not
only elucidating the effect of each mutation on the function of the
encoded protein, but also determining how the mutant protein
affects the epigenetic regulatory complexes in which it functions.
This would require future investigation of how the altered
function is inﬂuenced by the baseline epigenetic state of the target
cell of transformation, and how this altered function comple-
ments other somatic mutations that are required for the
development of overt cancer. The database developed by our
work will help to focus further studies on the cell lineages that
correspond to the tumour types in which speciﬁc mutations are
detected.
Methods
Patients and samples. The use of human tissues for sequencing was approved by
the institutional review boards of St Jude Children’s Research Hospital, Memorial
Sloan-Kettering Cancer Center and Washington University in St Louis (St Jude
IRB# FWA00004775, Protocol# XPD09-018). Written informed consent and/or
assent were obtained from patients and/or legal guardians at the time of the sur-
gical resection or bone marrow biopsy. Matched normal samples were obtained
either from peripheral blood, bone marrow or adjacent normal tissue. All leu-
kaemia samples have Z70% blasts. The tumour content for the four subtypes of
brain tumours, HGG, LGG, MB and EPD, exceeds 50, 67, 90 and 95%, respectively.
The tumour purity for solid tumours ranges from 48 to 96%.
Identiﬁcation of genes involved in chromatin modiﬁcation. We searched
multiple data sources to identify the proteins that: (1) bind a histone peptide, (2)
modify nascent histone amino acids, (3) are part of established complexes involved
in histone modiﬁcation, (4) reorganize nucleosomes or (5) modify or bind modiﬁed
genomic DNA. A core set of proteins was identiﬁed that is known to directly
modify histones or DNA13,27,28, bind directly to modiﬁed or nascent histones29,30
or alter chromatin state31. To expand our list to include additional homologues, we
searched UniProt database32 for the known histone reader domains (Bromo,
Tandem Bromo, Chromo, PHD, Tandem PHD, Tudor, Tandem, PWWP, MBT,
WD40, ADD, Ankyrin Repeats, ZF-CW and 14-3-3)29 and catalytic modiﬁcation
domains (such as SET and Jumonji)33. The list was further expanded to include
proteins within known complexes and potential complexes15–22,31. Potential
epigenetic protein complexes were identiﬁed by using the core set of genes to
search the STRING database (species¼ 9,606 and required score 4900) for
interaction partners34. The large numbers of proteins identiﬁed were culled down
by manually verifying that the interaction to a search protein was functionally
relevant to histone, DNA modiﬁcation or chromatin remodelling. All proteins were
assigned a functional class (writers, erasers, reader, remodel chromatin, modify
DNA, histone family, binding histone eraser and binding histone writer). In the
case where proteins can be grouped in multiple classes, each protein was only
assigned to the highest functional class available.
Sequencing and experimental veriﬁcation. WGS (n¼ 434) and WES (n¼ 244),
and analysis are described in detail elsewhere6,7. For 426 cases analysed by CC,
libraries used for the enrichment were constructed from repli-G WGA DNA
(Qiagen) with TruSeq DNA sample prep kits (Illumina), following manufacturer’s
recommendations. Probe set for capturing all coding exons of the 633 chromatin-
modifying genes was designed using Design Studio (Illumina). The resulting probe
set was then synthesized and provided as part of a TruSeq Custom Enrichment kit
(Illumina). Library hybridization and enrichment of the targeted regions was
conducted using the manufacturer’s instructions. The enriched libraries were then
sequenced on a HiSeq 2000 (Illumina) using V3 Chemistry (PE100 protocol), with
24 samples pooled per lane. Sequence data were analysed using the same methods
as those for WGS and WES. For cases that were not subjected to WGS or WES,
their TP53 mutation status was analysed by Sanger sequencing of coding exons
using ABI3730 (Applied Biosystems).
The majority of the putative variants were validated by NGS amplicon
sequencing using the Nextera XT library prep kit (Illumina) and sequenced on the
MiSeq (Illumina). Following an effective validation protocol35, the MiSeq paired-
end 150-cycle protocol was performed with variants called by MiSeq reporter—a
subset of the putative variants was validated by amplicon Sanger Sequencing using
an ABI3730 and the BigDye 3.1 cycle sequencing kit (Applied Biosystems).
Amplicons used for validation were generated from WGA DNA prepared
independently of the material used for the custom enrichment, with oligos
designed by software based on Primer3 (ref. 36). The PCR was performed with
20 ng of WGA DNA input using the AmpliTaq Gold 360 Master Mix (Life
Technologies) as per the manufacturer’s instructions. Samples with existing WGS
or WES data corroborating the SNVs or indels observed in the targeted enrichment
data were considered to be validated.
Functional and statistical signiﬁcance of top 15 genes. Loss-of-function
mutations include indels or SNVs that result in frame shift, nonsense or affect
splice sites. Functional signiﬁcance of a missense mutation is determined for
USP7 by majority rule (Z50% predict deleterious) using Polyphen37 (probably_
deleterious and greater), Sift38 (deleterious) and Mutation Assessor39 (medium
assignment or greater). Known activating mutations were annotated based on
literature search.
Mutational signiﬁcance was calculated for recurrently mutated genes. The
background mutation rate (BMR) for WGS samples were estimated on the basis of
mutations in non-coding, non-repetitive regions (that is, Tier3 data) and the
disease-speciﬁc median BMR estimate was used for the BMR of WES and CC
samples from the same disease type. The probability of a gene mutated in a speciﬁc
sample under the null hypothesis of random background mutation was estimated
from the amino-acid length and the BMR of the sample. The probability of
observing a gene mutated in at least n samples under the null hypothesis of random
background mutation was estimated using a one tail Poisson binomial distribution.
Analysis of novel mutations in leukaemia. To determine whether the mutations
identiﬁed in leukaemia are novel, we ﬁrst searched PubMed for all genes with
recurrent SNVs with and without the term ‘cancer’. These genes were also used to
mine the COSMIC data set v63 (downloaded 18 February 2013). To further classify
novel genes within leukaemia, a similar PubMed search was performed with the
search term ‘leukaemia’. This was accompanied by data mining of COSMIC to
identify genes with mutations associated with the term ‘haematopoieti-
c_and_lymphoid_tissue’. The associated publications were reviewed to determine
whether the mutations in published literature were identiﬁed in paediatric or adult
patients.
Structural modelling and epigenetic regulator network. The structure of the
catalytic domain of USP7 (Fig. 3b) bound to ubiquitin aldehyde (PDB: 1NBF) was
obtained from the PDB26,40. Mutations and graphics were generated using
Pymol41. The network graph was generated in Cytoscape42.
USP7 mutagenesis and transfection. To demonstrate loss-of-function, two
missense mutations identiﬁed in TALL (C300R and D305G) were introduced by
site-direct mutagenesis (Agilent, Santa Clara, CA) on a wild-type USP7 cDNA
construct (plasmid pCl-neo-Flag-HAUSP was deposited by Dr Bert Vogelstein at
addgene). The following primers were used 50-CATGATGTTCAGGAGCTTCGT
CGAGTGTTGCTCGA-30 for C300R-F and 50-TCGAGCAACACTCGACGAAG
CTCCTGAACATCATG-30 for C300R-R, and 50-GCTTTGTCGAGTGTTGCTCG
GTAATGTGGAAAATAAGATGA-30 for D305G-F and 50-TCATCTTATTTTCC
ACATTACCGAGCAACACTCGACAAAGC-30 for D305G-R. All constructs
were sequenced for veriﬁcation (Supplementary Fig. 8). In all, 3 105 293T cells
(ATCC, catalogue # CRL-11268) per well of a six-well plate were cultured in
DMEM (Lonza, Walkersville, MD) with 10% of FBS (Sigma, Atlanta, GA). Two
microgram of plasmid DNA was transfected into cells with X-tremeGENE HP
DNA transfection reagent (Roche, Indianapolis, IN).
Western blot. Total protein of 293T cells was extracted at 72 h post transfection.
Protein levels of USP7, total H2B and H2B ubiquityl Lys120 were detected by
western blot with indicated antibodies. Human HAUSP (USP7) (catalogue # PA5-
17179) and GAPDH (catalogue # MA5-15738) antibodies were purchased from
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Thermo Scientiﬁc (Rockford, IL), human H2B (catalogue # 39126) and
H2BK120ub1 (catalogue # 39624) antibodies were purchased from Active Motif
(Carlsbad, CA). Secondary goat anti-rabbit (catalogue # ab97051) or anti-mouse
(catalogue # ab97265) antibodies were purchased from Abcam (Cambridge, MA).
Brieﬂy, the blots were incubated in the 1:1,000 diluted primary antibodies over-
night at 4 C and followed by incubating in 1:5,000 diluted secondary antibodies.
The protein bands were detected by SuperSignal West Femto Maximum Sensitivity
Substrate (catalogue # 34096) purchased from Thermo Scientiﬁc (Rockford, IL).
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